Skip to content

Eero Castrén

11 papers in the library · 666 citations · publishing 2006-2026

Papers

Sort Most recent Most cited

Surgical Protocol for a Large, Resealable Cranial Window Enabling Longitudinal, Multi-Modal Electrophysiology Recordings of Mouse Default Mode Network.

Journal of Visualized Experiments May 29, 2026 Tommi Kiiso, Paula Partanen, Keyrstin Jacobs et al.

The default mode network (DMN) is a central, large-scale brain network implicated in a range of cognitive functions and neuropsychiatric disorders, such as major depressive disorder (MDD). Studying the DMN's complex dynamics in animal models provides invaluable insights into its function in both healthy and pathological states. However, performing stable, long-term, large-scale...

Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway.

Biological Psychiatry February 1, 2025 Cassiano Ricardo Alves Faria Diniz, Ana Paula Crestani, Plinio Cabrera Casarotto et al. 15 citations

Diverse antidepressants were recently described to bind to TrkB (tyrosine kinase B) and drive a positive allosteric modulation of endogenous BDNF (brain-derived neurotrophic factor). Although neurotrophins such as BDNF can bind to p75NTR (p75 neurotrophin receptor), their precursors are the high-affinity p75NTR ligands. While part of an unrelated receptor family capable of inducing completely...

Rethinking the role of TRKB in the action of antidepressants and psychedelics.

Trends in Neurosciences November 1, 2024 Cecilia Anna Brunello, Cecilia Cannarozzo, Eero Castrén 29 citations

Antidepressant drugs promote neuronal plasticity, and activation of brain-derived neurotrophic factor (BDNF) signaling through its receptor neuronal receptor tyrosine kinase 2 (NTRK2 or TRKB) is among the critical steps in this process. These mechanisms are shared by typical slow-acting antidepressants, fast-acting ketamine, and psychedelic compounds, although the cellular targets of each drug...

Antidepressants enter cells, organelles, and membranes.

Neuropsychopharmacology 2024 Zack Blumenfeld, Kallol Bera, Eero Castrén et al. 10 citations

We begin by summarizing several examples of antidepressants whose therapeutic actions begin when they encounter their targets in the cytoplasm or in the lumen of an organelle. These actions contrast with the prevailing view that most neuropharmacological actions begin when drugs engage their therapeutic targets at extracellular binding sites of plasma membrane targets-ion channels, receptors,...

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.

Neuroscience Applied 2024 Drummond E-Wen Mcculloch, Juan Pablo Lopez, Christina Dalla et al. 2 citations

Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated for their clinical effects in various brain disorders. At the ECNP "New Frontiers meeting" in March 2023, scientific experts in psychedelics met to identify key knowledge gaps in the mechanism of action of psychedelics as investigated using...

DOI: 10.1016/j.nsa.2023.103929 (opens in new tab) Full text (opens in new tab) Hallucinogen investigation Psychoactive drug research Entheogen research Psychedelic compounds +15

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.

Journal of Neuroscience November 8, 2023 Lindsay P. Cameron, Joseph Benetatos, Vern Lewis et al. 88 citations

Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects and unique mechanisms of action. These compounds exert their primary effects through activating serotonin 5-HT2A receptors, found predominantly in cortical regions. By interacting with these receptors, serotonergic psychedelics induce alterations in...

DOI: 10.1523/jneurosci.1384-23.2023 (opens in new tab) Full text (opens in new tab) Psychedelics Brain chemistry Mental health Pharmacology

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Nature Neuroscience June 1, 2023 Rafael Moliner, Mykhailo Girych, Vera Kovaleva et al. 439 citations

Abstract Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved antidepressants. We recently reported that pharmacologically diverse antidepressants, including fluoxetine and ketamine, act by binding to TrkB, the receptor for BDNF. Here we show that lysergic acid diethylamide (LSD) and psilocin directly bind to...

DOI: 10.1038/s41593-023-01316-5 (opens in new tab) Full text (opens in new tab) Neuroplasticity Brain-derived neurotrophic factor Receptor Neurotrophic factors

Ketamine and its metabolite 2R,6R‐hydroxynorketamine promote ocular dominance plasticity and release tropomyosin‐related kinase B from inhibitory control without reducing perineuronal nets enwrapping parvalbumin interneurons

March 1, 2023 Cecilia Cannarozzo, Anna Rubiolo, Plínio Casarotto et al.

Ketamine has been described as a fast‐acting antidepressant, exerting effects in depressed patients and in preclinical models with a rapid onset of action. The typical antidepressant fluoxetine is known to induce plasticity in the adult rodent visual cortex, as assessed by a shift in ocular dominance, a classical model of brain plasticity, and a similar effect has been described for ketamine...

Psychedelics and Neural Plasticity: Therapeutic Implications.

Journal of Neuroscience November 1, 2022 Steven F. Grieco, Eero Castrén, Gitte M. Knudsen et al. 83 citations

Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural attitudes toward them are changing, and scientists are once again investigating the neural mechanisms through which these drugs impact brain function. The significance of this research direction is reflected by recent work, including work presented by these authors at the 2022 meeting of the Society for...

The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.

Neuropharmacology January 2012 Jesse S O Lindholm, Henri Autio, Liisa Vesa et al.

Accumulating evidence suggests that biogenic amine-based antidepressants act, at least in part, via regulation of brain-derived neurotrophic factor (BDNF) signaling. Biogenic amine-based antidepressants increase BDNF synthesis and activate its signaling pathway through TrkB receptors. Moreover, the antidepressant-like effects of these molecules are abolished in BDNF deficient mice....

Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment.

Journal of Neurochemistry November 2006 Makoto Takahashi, Akiyoshi Kakita, Takashi Futamura et al.

Brain-derived neurotrophic factor (BDNF) is involved in synaptic development and plasticity, and alterations in BDNF expression or signaling are implicated in drug addiction and psychiatric diseases, such as depression and schizophrenia. In this study, we administered phencyclidine to postnatal and adult rats with different time schedules, and determined the correlations between BDNF expression...